- Large 106 cm axial PET field of view enables simultaneous whole-body imaging from top of head to thigh
- Industry’s most sensitive extended field of view scanner¹ designed for clinical and research use
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner designed for clinical use as well as translational research – or the application of scientific research to create therapies and procedures that improve health outcomes. In this manner, the Biograph Vision Quadra expands precision medicine.
In addition to the 3.2 mm silicon photomultiplier (SiPM) detector technology and Time of Flight (ToF) performance that are cornerstones of the established Biograph Vision PET/CT scanner, the Biograph Vision Quadra has an extended 106 cm axial field of view (FoV), which is four times the PET axial FoV of the Biograph Vision 600. These technological features deliver significantly increased effective sensitivity¹ and allow the clinician to image the average patient dynamically from the top of the head to the thigh in just one position. Thanks to the scanner’s extended axial FoV, the clinician can examine patient anatomy during radiopharmaceutical uptake over time. The combination of SiPM detectors and extended axial FoV permits more anatomical coverage in one bed position than a standard PET/CT scanner, enabling fast scanning at low patient radiation dose.
“The Biograph Vision Quadra breaks through current clinical scanner limitations by simultaneously imaging all vital organs in a single field of view,” said John Khoury, Head of the Molecular Imaging business at Siemens Healthineers North America. “This new system helps open the door to better understand disease.”
Since the Biograph Vision Quadra can be sited in the same clinical space as traditional PET/CT scanners, institutions do not need to build a large new room to house the scanner.
Contact for Journalists
Phone: (484) 868-8346; Email: email@example.com
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare.
Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients.
In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.